资讯

Le Lézard21 小时
Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 ...
Johnson & Johnson today announced first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200?an intravesical gemcitabine releasing system?for patients with certain types of bladder ...
Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve ...
Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational ...